Related Experiment Video
Updated: Jun 18, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Targeted therapy in high grade serous ovarian Cancer: A literature review
Kaitlyn Dinkins1, Wade Barton1, Lauren Wheeler2
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL.
Abstract:
Ovarian cancer continues to have a high mortality rate despite therapeutic advances. Traditionally, treatment has focused on surgery followed by systemic platinum- based chemotherapy. Unfortunately, most patients develop resistance to platinum agents, highlighting the need for targeted therapies. PARP inhibitors and anti-angiogenic agents, such as bevacizumab, have more recently changed upfront therapy. Unfortunately, other targeted therapies including immunotherapy have not seen the same success. Emerging therapeutic targets and modalities such as small molecule tyrosine kinase inhibitors, lipid metabolism targeting agents, gene therapy, ribosome targeted drugs as well as several other therapeutic classes have been and are currently under investigation. In this review, we discuss targeted therapies in high grade serous ovarian cancer from preclinical studies to phase III clinical trials.
Insights
High-grade serous ovarian cancer has a poor prognosis due to treatment resistance. This review explores novel targeted therapies beyond traditional chemotherapy, including PARP inhibitors and emerging agents, for improved ovarian cancer treatment.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ovarian cancer, particularly high-grade serous ovarian cancer (HGSOC), exhibits high mortality rates.
- Conventional treatments like surgery and platinum-based chemotherapy are often met with resistance.
- Recent advances include PARP inhibitors and anti-angiogenic agents, but other targeted therapies show limited success.
Purpose of the Study:
- To review targeted therapies for high-grade serous ovarian cancer.
- To cover therapeutic strategies from preclinical research to clinical trials.
Main Methods:
- Literature review of preclinical studies and clinical trials.
- Discussion of various targeted therapy classes.
Main Results:
- Platinum resistance remains a significant challenge in ovarian cancer treatment.
- PARP inhibitors and bevacizumab have impacted upfront therapy.
- Immunotherapy has not yet achieved comparable success in ovarian cancer.
Conclusions:
- Emerging targeted therapies, including small molecule tyrosine kinase inhibitors and lipid metabolism agents, are under investigation.
- Gene therapy and ribosome-targeted drugs represent other promising therapeutic avenues.
- Continued research into novel targeted modalities is crucial for advancing HGSOC treatment.
More Related Videos
14:25Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
Published on: November 28, 2010
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...